Stefano Iacobelli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11657434/publications.pdf

Version: 2024-02-01

96	5,831	101543	74163
papers	citations	36 h-index	75 g-index

96	96	96	7116
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. Glycobiology, 2007, 17, 541-552.	2.5	844
2	Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?. Trends in Immunology, 2002, 23, 313-320.	6.8	493
3	Elevated Serum Cytokines Correlated with Altered Behavior, Serum Cortisol Rhythm, and Dampened 24-Hour Rest-Activity Patterns in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2005, 11, 1757-1764.	7.0	231
4	Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Research, 2002, 62, 840-7.	0.9	207
5	Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group. Journal of Clinical Oncology, 2006, 24, 3562-3569.	1.6	200
6	Circadian Rhythm in Rest and Activity: A Biological Correlate of Quality of Life and a Predictor of Survival in Patients with Metastatic Colorectal Cancer. Cancer Research, 2009, 69, 4700-4707.	0.9	195
7	Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. International Journal of Cancer, 2000, 85, 545-554.	5.1	194
8	Effects of Light and Food Schedules on Liver and Tumor Molecular Clocks in Mice. Journal of the National Cancer Institute, 2005, 97, 507-517.	6.3	188
9	90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconjugate Journal, 2002, 19, 551-556.	2.7	148
10	Phospholipase CÎ³1 Is Required for Metastasis Development and Progression. Cancer Research, 2008, 68, 10187-10196.	0.9	135
11	Galectinâ€3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. FEBS Letters, 2000, 473, 311-315.	2.8	131
12	Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway by Inositol Pentakisphosphate Results in Antiangiogenic and Antitumor Effects. Cancer Research, 2005, 65, 8339-8349.	0.9	126
13	Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology, 2006, 16, 210-220.	2.5	114
14	Improved Tumor Control through Circadian Clock Induction by Seliciclib, a Cyclin-Dependent Kinase Inhibitor. Cancer Research, 2006, 66, 10720-10728.	0.9	109
15	Fucans, but Not Fucomannoglucuronans, Determine the Biological Activities of Sulfated Polysaccharides from Laminaria saccharina Brown Seaweed. PLoS ONE, 2011, 6, e17283.	2.5	104
16	The mechanism involved in the regulation of phospholipase CÎ³1 activity in cell migration. Oncogene, 2002, 21, 6520-6529.	5.9	103
17	Prediction of overall survival through circadian restâ€activity monitoring during chemotherapy for metastatic colorectal cancer. International Journal of Cancer, 2012, 131, 2684-2692.	5.1	102
18	Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer, 2004, 101, 1609-1615.	4.1	95

#	Article	IF	Citations
19	Glycoprotein 90K/MACâ€2BP interacts with galectinâ€1 and mediates galectinâ€1â€“induced cell aggregation. International Journal of Cancer, 2001, 91, 167-172.	5.1	95
20	Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway. Oncogene, 2004, 23, 1754-1765.	5.9	89
21	Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to Î±-interferon therapy in chronic HCV hepatitis patients. Journal of Hepatology, 1996, 25, 212-217.	3.7	88
22	Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Research, 2002, 62, 2535-9.	0.9	88
23	Antibody-Drug Conjugates: The New Frontier of Chemotherapy. International Journal of Molecular Sciences, 2020, 21, 5510.	4.1	83
24	Axillary Lymph Node Nanometastases Are Prognostic Factors for Disease-Free Survival and Metastatic Relapse in Breast Cancer Patients. Clinical Cancer Research, 2006, 12, 6696-6701.	7.0	71
25	Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer. Journal of Pathology, 2017, 241, 350-361.	4.5	66
26	LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. Journal of Molecular Medicine, 2013, 91, 83-94.	3.9	63
27	Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. Oncotarget, 2015, 6, 3932-3946.	1.8	60
28	Antiproliferative effects of somatostatin and the somatostatin analog SMS 201-995 on three human breast cancer cell lines. Journal of Cancer Research and Clinical Oncology, 1988, 114, 306-308.	2.5	56
29	Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patients. Breast Cancer Research and Treatment, 1988, 11, 19-30.	2.5	52
30	Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target. Journal of Translational Medicine, 2021, 19, 405.	4.4	50
31	Lack of Expression of Galectin-3 Is Associated With a Poor Outcome in Node-Negative Patients With Laryngeal Squamous-Cell Carcinoma. Journal of Clinical Oncology, 2002, 20, 3850-3856.	1.6	42
32	A Dietary Tomato Supplement Prevents Prostate Cancer in TRAMP Mice. Cancer Prevention Research, 2010, 3, 1284-1291.	1.5	42
33	Overexpression of activated phospholipase CÎ³1 is a risk factor for distant metastases in T1â€T2, N0 breast cancer patients undergoing adjuvant chemotherapy. International Journal of Cancer, 2013, 132, 1022-1031.	5.1	41
34	Two new estrogen-supersensitive variants of the MCF-7 human breast cancer cell line. Breast Cancer Research and Treatment, 1983, 3, 23-32.	2.5	40
35	Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. Cancer, 2013, 119, 2564-2573.	4.1	40
36	Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. Blood, 2000, 96, 3282-3285.	1.4	39

#	Article	IF	Citations
37	Prediction of Survival by Neutropenia According To Delivery Schedule of Oxaliplatinâ€“5-Fluorouracilâ€“Leucovorin for Metastatic Colorectal Cancer in a Randomized International Trial (EORTC 05963). Chronobiology International, 2011, 28, 586-600.	2.0	37
38	PTP-PEST phosphatase variations in human cancer. Cancer Genetics and Cytogenetics, 2006, 170, 48-53.	1.0	36
39	High expression of 90K (Macâ€2 BP) is associated with poor survival in nodeâ€negative breast cancer patients not receiving adjuvant systemic therapies. International Journal of Cancer, 2009, 124, 333-338.	5.1	36
40	LIVER CIRCADIAN CLOCK, A PHARMACOLOGIC TARGET OF CYCLIN-DEPENDENT KINASE INHIBITOR SELICICLIB. Chronobiology International, 2009, 26, 1169-1188.	2.0	35
41	Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer. , 1996, 68, 34-38.		34
42	A 90-kDa Protein Serum Marker for the Prediction of Progression to AIDS in a Cohort of HIV-1+Homosexual Men. AIDS Research and Human Retroviruses, 1993, 9, 811-816.	1.1	31
43	Biological indicators of prognosis in Ewing's sarcoma: An emerging role for lectin galactosideâ€binding soluble 3 binding protein (LGALS3BP). International Journal of Cancer, 2010, 126, 41-52.	5.1	31
44	Role of 90K protein in asthma and TH2-type cytokine expression. Annals of Allergy, Asthma and Immunology, 2004, 93, 485-492.	1.0	30
45	Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer. Journal of Cancer Research and Clinical Oncology, 2012, 138, 221-229.	2.5	30
46	Secreted Gal-3BP is a novel promising target for non-internalizing Antibodyâ€“Drug Conjugates. Journal of Controlled Release, 2019, 294, 176-184.	9.9	30
47	HER3 targeting with an antibodyâ€drug conjugate bypasses resistance to antiâ€HER2 therapies. EMBO Molecular Medicine, 2020, 12, e11498.	6.9	30
48	90K (Mac-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells. , 1998, 79, 23-26.		29
49	ErbB-3 activation by NRG-1Î² sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs). Oncotarget, 2015, 6, 16902-16911.	1.8	29
50	PARP co-activates B-MYB through enhanced phosphorylation at cyclin/cdk2 sites. Oncogene, 2001, 20, 8167-8174.	5.9	27
51	The Immune Stimulatory Protein 90K Increases Major Histocompatibility Complex Class I Expression in a Human Breast Cancer Cell Line. Biochemical and Biophysical Research Communications, 1996, 225, 617-620.	2.1	26
52	EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo. Translational Oncology, 2013, 6, 676-IN9.	3.7	26
53	Prognostic relevance of LGALS3BP in human colorectal carcinoma. Journal of Translational Medicine, 2015, 13, 248.	4.4	26
54	Effects of type-I and -II interferons on 90K antigen expression in ovarian carcinoma cells. International Journal of Cancer, 1994, 59, 808-813.	5.1	23

#	Article	IF	Citations
55	The 90K Protein Increases Major Histocompatibility Complex Class I Expression and Is Regulated by Hormones, Î³-Interferon, and Double-Strand Polynucleotides. Endocrinology, 2004, 145, 4728-4736.	2.8	23
56	EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma. Journal of Controlled Release, 2018, 277, 48-56.	9.9	23
57	EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma. Oncotarget, 2017, 8, 95412-95424.	1.8	22
58	Inhibition of Tumor Growth and Angiogenesis by SP-2, an Antiâ€“Lectin, Galactoside-Binding Soluble 3 Binding Protein (LGALS3BP) Antibody. Molecular Cancer Therapeutics, 2014, 13, 916-925.	4.1	21
59	Effects of antiestrogen and progestin on immune functions in breast cancer patients. Cancer, 1988, 61, 2214-2218.	4.1	19
60	Relief of Symptoms After Gefitinib Is Associated With Improvement of Rest/Activity Rhythm in Advanced Lung Cancer. Journal of Clinical Oncology, 2007, 25, e17-e19.	1.6	19
61	Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. Journal of Cancer Research and Clinical Oncology, 2013, 139, 269-280.	2.5	19
62	Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1â€“induced cell aggregation. International Journal of Cancer, 2001, 91, 167-172.	5.1	18
63	An Antibody-based Blood Test Utilizing a Panel of Biomarkers as a New Method for Improved Breast Cancer Diagnosis. Biomarkers in Cancer, 2013, 5, BIC.S13236.	3.6	18
64	Induced Protein Synthesis and Oestradiol Binding to the Nuclei in the Rat Uterus. Nature: New Biology, 1973, 245, 154-155.	4.5	17
65	Glucocorticoid receptor studies in human leukemia. The Journal of Steroid Biochemistry, 1981, 15, 261-268.	1.1	16
66	The 90K Tumor-Associated Antigen and Clinical Progression in Human Immunodeficiency Virus Infection. Journal of Acquired Immune Deficiency Syndromes, 1995, 10, 450-456.	0.3	16
67	Identification of the Tumor Antigen 90K Domains Recognized by Monoclonal Antibodies SP2 and L3 and Preparation and Characterization of Novel Anti-90K Monoclonal Antibodies. Biochemical and Biophysical Research Communications, 1997, 232, 367-372.	2.1	16
68	Expression of the 90K Tumor-Associated Protein in Benign and Malignant Melanocytic Lesions. Journal of Investigative Dermatology, 2002, 119, 187-190.	0.7	16
69	Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma. Cancers, 2020, 12, 2989.	3.7	16
70	Isolation and Functional Characterization of the Human 90K Promoter. Genomics, 1999, 57, 268-278.	2.9	14
71	Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma. Oncotarget, 2017, 8, 60368-60377.	1.8	13
72	Hormone receptor status in human endometrial adenocarcinoma. Cancer, 1989, 64, 2572-2578.	4.1	12

#	Article	IF	Citations
73	Expression of the 90K Immunostimulator Gene Is Controlled by a Promoter with Unique Features. Journal of Biological Chemistry, 1997, 272, 3674-3682.	3.4	12
74	Long-Term Outcome of Neoadjuvant Endocrine Therapy with Aromatase Inhibitors in Elderly Women with Hormone Receptor-Positive Breast Cancer. Annals of Surgical Oncology, 2014, 21, 1575-1582.	1.5	11
75	Surface-enhanced Raman scattering (SERS)â€“based immunosystem for ultrasensitive detection of the 90K biomarker. Analytical and Bioanalytical Chemistry, 2020, 412, 7659-7667.	3.7	11
76	Improvement of urinary tract symptoms and quality of life in benign prostate hyperplasia patients associated with consumption of a newly developed whole tomato-based food supplement: a phase II prospective, randomized double-blinded, placebo-controlled study. Journal of Translational Medicine, 2021, 19, 24.	4.4	10
77	Antibody to estrogen-induced protein (IP) and quantification of the protein in rat uterus by a radioimmunoassay. Biochemical and Biophysical Research Communications, 1977, 76, 1230-1237.	2.1	9
78	Recombinant alpha-2b-interferon enhances the circulating levels of a 90-kilodalton (K) tumor-associated antigen in patients with gynecologic and breast malignancies. Cancer, 1990, 65, 1325-1328.	4.1	8
79	Prognostic Value of a Novel Interferon-inducible 90K Tumor Antigen. Annals of the New York Academy of Sciences, 1996, 784, 288-293.	3.8	8
80	Upstream Stimulatory Factor Regulates Constitutive Expression and Hormonal Suppression of the 90K (Mac-2BP) Protein. Endocrinology, 2007, 148, 3507-3517.	2.8	8
81	Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1229-1240.	2.5	8
82	Lack of mother-to-child HIV-1 transmission is associated with elevated serum levels of 90 K immune modulatory protein. Aids, 2000, 14, F41-F45.	2.2	7
83	EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors. Pharmaceutics, 2021, 13, 483.	4.5	7
84	Presence and steroid inducibility of glutamine synthetase in human leukemic cells. The Journal of Steroid Biochemistry, 1983, 19, 1665-1670.	1.1	6
85	Circulating Autoantibodies to LGALS3BP: A Novel Biomarker for Cancer. Disease Markers, 2013, 35, 747-752.	1.3	6
86	Circadian robustness as an independent predictor of prolonged progression-free survival (PFS) and overall survival (OS) in 436 patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2012, 30, 464-464.	1.6	6
87	Growth promoting influences of estradiol, epidermal growth factor, and insulin on human breast cancer: Evidence for differential mechanism of action on tumor cells in vitro. Breast Cancer Research and Treatment, 1985, 6, 255-256.	2.5	5
88	Recombinant alpha-2b-interferon dynamic test as a potential tool in predicting disease status during second look in ovarian cancer. A preliminary report. Cancer, 1991, 68, 2582-2585.	4.1	5
89	Sentinel Node and Bone Marrow Micrometastases and Nanometastases. Current Breast Cancer Reports, 2010, 2, 96-106.	1.0	4
90	Efficacy and Safety of LycoprozenÂ®, a Novel Tomato-Based Food Supplement in Patients with Benign Prostatic Hyperplasia. International Journal of Nutrition, 2018, 3, 1-5.	0.7	3

#	Article	IF	Citations
91	Gal-3BP in Viral Infections: An Emerging Role in Severe Acute Respiratory Syndrome Coronavirus 2. International Journal of Molecular Sciences, 2022, 23, 7314.	4.1	3
92	Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. Blood, 2000, 96, 3282-3285.	1.4	2
93	Increased Gal-3BP plasma levels in hospitalized patients infected with SARS-CoV-2. Clinical and Experimental Medicine, 2022, , 1.	3.6	2
94	Overexpression of PY1289-HER3 in sporadic pulmonary carcinoid from patients bearing MEN1 gene variants. Oncology Letters, 2016, 12, 453-458.	1.8	1
95	Steroid Hormone Receptors in Endocrine-Related Tumors. , 1984, , 161-193.		1
96	Liver Circadian Clock, a Pharmacologic Target of Cyclin-Dependent Kinase Inhibitor Seliciclib. Chronobiology International, 2009, 26, 1169-1188.	2.0	0